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Abstract
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the
treatment decision-makingof patientswith cancer,whomaybeat higher risk of developing a severe anddeadlySARS-CoV-
2 infectioncomparedwith thegeneralpopulation.Thehealthcareemergency is forcing the reshapingof thedailyassessment
between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments.To
guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in
Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with
gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak,
with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.
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In December 2019, Chinese authorities firstly reported a cluster
of cases of severe pneumonia in Wuhan (Hubei province). The
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https://doi.org/10.1016/j.clcc.2020.05.004(SARS-CoV-2) was deemed responsible for coronavirus disease
2019 (COVID-19) and the pandemic outbreak. This highly in-
fectious disease is usually associated with flu-like symptoms but may
rapidly evolve to severe interstitial pneumonia and even death,
particularly in older patients with comorbidities, including cancer.
As of April 4, 2020 Italian authorities reported 124,632 SARS-
CoV2 confirmed cases and 15,362 deaths, thus representing the
highest number of COVID-19-related deaths in the world.1
A Chinese single-institution cohort study showed that patients
with cancer may be at higher risk of SARS-CoV-2 infection
compared with the general population,2 and a nationwide study
associated a history of cancer with higher risk of severe events,
defined as intensive care unit admission, invasive ventilation, or
death.3 Additionally, because nosocomial transmission was identi-
fied in up to 41.3% of hospitalized patients,4 hospital admissions or
repeated clinic visits clearly represent a crucial source of contagion.Clinical Colorectal Cancer Month 2020 - 1
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Practical Recommendations for GI Oncology During COVID-19 OutbreakOn top of their disease, patients with cancer face several threats
related to their frequent hospital accesses: the presence of cancer-
related and treatment-related immune suppression and coexisting
comorbidities.
The risk of hospital transmission of SARS-CoV-2 may be
reduced, thanks to the screening of patients and staff and by
minimizing face-to-face interactions.5 Furthermore, Hanna et al
provided a general framework to prioritize the use of systemic
chemotherapy or radiotherapy during this global emergency, taking
into account the magnitude of treatment benefit and the potential
negative impact of treatment delays/interruptions on outcomes.6
However, there is no cancer-specific recommendation yet, particu-
larly for curable disease, on how to choose less toxic or more easy-to-
administer treatments without jeopardizing survival outcomes.
The National Cancer Institute of Milan (INT) is a comprehen-
sive cancer center located in the Lombardy region, which accounts
by itself for more than a half of the COVID-19-related deaths in
Italy so far. In February 2020, INT faced the challenge of pro-
foundly reorganizing its daily routine and procedures at an un-
precedented pace to maintain its patients with cancer as safe as
possible from COVID-19 and, at the same time, guarantee
adequate levels of care. In few weeks, our Gastrointestinal Oncology
Unit has elaborated Coronavirus-adapted treatment guidelines and
regimens, measures for patient information and support and pro-
cedures for dynamic up- and downscaling of clinical activities and
research.
Here, we describe how our daily clinical practice has changed due
to the COVID-19 outbreak, with the aim of providing useful rec-
ommendations for physicians that are facing the same challenges
worldwide.
Methods
Since the beginning of the Lombardy outbreak in February 2020,
a Gastrointestinal Oncology task force drafted the new Coronavirus-
adapted institutional guidelines for gastrointestinal cancers. The
multidisciplinary panel also included an external consultant (C.C.),
member of the steering committee of the Italian Association of
Medical Oncology (AIOM) Guidelines and based in a less impacted
Italian region, with the aim to minimize the potential bias related to
physicians’ stress condition and burnout.
Treatment decisions were discussed on an individual basis, and,
whenever necessary, multidisciplinary meetings were held as
routinely via video or call conference. Phone screening surveying
patients’ conditions, symptoms, latest radiologic evaluation, and
contact with potential infected subjects was carried out on a daily
basis.
Table 1 summarizes our recommendations according to disease
subtype.
Gastric and Gastroesophageal
Cancer
For perioperative or adjuvant chemotherapy of patients with
locally advanced gastric or gastroesophageal junction adenocarci-
noma, the choice of multimodality treatment over surgery alone was
made after careful evaluation of each individual risk-benefit profile.
First, microsatellite instability (MSI) testing was performed for all
patients to avoid perioperative/adjuvant treatments in those withnical Colorectal Cancer Month 2020MSI-high, R0 resectable cancers.7 Based on a multidisciplinary team
assessment, preoperative chemotherapy was recommended only for
patients with age < 70 years and resectable high-risk disease.
Oxaliplatin-based doublets were the treatment of choice for patients
with node-positive disease assessed by both fluorine-18 fluo-
rodeoxyglucose positron emission tomography/computed tomogra-
phy (FDG-PET/CT) scan and endoscopic ultrasonography and for
selected patients with cT3N0 tumors with adverse prognostic fea-
tures (ie, diffuse histotype) or technical risks of incomplete resection
(ie, gastroesophageal junction cancers). FLOT (docetaxel, oxalipla-
tin, and fluorouracil/leucovorin) triplet chemotherapy, which is
associated with increased survival at the cost of a higher risk of
toxicity,8 was recommended only for cT4 tumors and in those cases
with unacceptable risk of positive (R1/R2) tumor margins. For
patients with gastroesophageal junction adenocarcinoma, the use of
neoadjuvant chemoradiation was discouraged even for Siewert 1 and
2 tumors. Regarding postoperative chemotherapy, we carefully
assessed the patient’s health condition and nutritional status after
gastrectomy, and the choice between adjuvant single-agent fluo-
ropyrimidines (capecitabine) or CAPOX (capecitabine plus oxali-
platin) was made based on pathologic stage and individual risk of
relapse.9,10
For patients with human epidermal growth factor receptor 2
(HER2)-negative metastatic gastric cancer (mGC), the most
commonly used first-line chemotherapy regimens are represented by
combinations of fluoropyrimidines and platinums, with or without
a third chemotherapy agent. Given the limited overall survival
advantage provided by triplet chemotherapy at the cost of significant
toxicity, doublet regimens are usually preferred in the clinical
practice. Moreover, the administration of cisplatin requires pro-
tracted hydration and may cause severe vomiting, nephrotoxicity,
and grade 3 to 4 neutropenia worthy of hospital admissions or
intravenous supportive treatments. Several studies demonstrated the
non-inferiority of oxaliplatin compared with cisplatin as part of
combination regimens.11,12 Therefore, the choice of CAPOX
regimen was preferred over FOLFOX (folinic acid, 5-fluorouracil,
and oxaliplatin) thanks to its 3-weekly schedule and the oral
administration of fluoropyrimidine, with no need for infusion
pumps and central venous catheters.11-13 For dysphagic patients
needing nutritional support, initial treatment with FOLFOX infu-
sional regimen was shifted to CAPOX as soon as the symptoms’
resolution allowed it.
For patients with HER2-positive mGC, phase II non-
randomized trials of trastuzumab added to standard CAPOX
demonstrated an advantageous safety profile of this chemotherapy
backbone and efficacy outcomes in line with those achieved with
cisplatin-based regimens in the phase III ToGA registration
trial.14-16 Therefore, we selected CAPOX-trastuzumab for 6 cycles
followed by maintenance with single-agent trastuzumab as the
strategy of choice.
Even if irinotecan, taxanes, or the anti-vascular endothelial
growth factor receptor 2 (VEGFR-2) monoclonal antibody ramu-
cirumab represent evidence-based second-line treatment
options,17-19 the absolute survival benefit is quite limited and
should be carefully evaluated based on the relevant toxicity risk and
individual patients’ life expectancy.20 The optimal candidates for
second-line therapy may be identified based on Eastern Cooperative
Table 1 Summary of Coronavirus-adapted Institutional Guidelines at the National Cancer Institute of Milan, Lombardy Region, Italy
Gastric and gastroesophageal cancer
Pre (peri)-operative treatment MSI-high cancer and R0 resectable or age > 70 years:
Not recommended
Node-positive or cT3N0 tumors with adverse prognostic/technical features:
CAPOX
cT4 stage or high-risk of R1/R2 resection:
FLOT
CRT for gastroesophageal junction cancers (including Siewert 1-2):
Not recommended
Adjuvant MSI-high cancer:
Not recommended
Based on pathologic stage and individual risk of relapse:
capecitabine
CAPOX
First line HER2-negative:
CAPOX
HER2-positive:
CAPOX þ trastuzumab for 6 cycles followed by trastuzumab maintenance
Second line Paclitaxel þ ramucirumab (modified biweekly regimen: mRAINBOW)
Ramucirumab contraindicated or not available:
Three-weekly irinotecan/docetaxel
>Third line Not recommended
Pancreatic cancer
Pre (peri)-operative treatment Resectable cancer:
Upfront resection
Borderline resectable cancer:
Multidisciplinary discussion (evaluating age, ECOG PS, comorbidities, and risk factors)
Adjuvant ECOG PS 0, < 70 years old patients, based on pathologic stage, individual risk of relapse/toxicity, and comorbidities:
Consider modified FOLFIRINOX (consider delaying treatment up to 12 weeks after surgery).
First line Nab-paclitaxel þ gemcitabine, biweekly
BRCA-mutated disease:
Oxaliplatin-based doublets with a stop-and-go approach
Olaparib maintenance only if residual grade  2 neuropathy after oxaliplatin-based induction
ECOG PS  2 patients and/or extensive comorbidities:
Consider best supportive care alone
>Second line Only in highly selected cases, ECOG PS 0-1
Biliary tract cancers
Adjuvant Based on pathologic stage, individual risk of relapse/toxicity, and comorbidities:
Capecitabine (consider delaying treatment up to 16 weeks after surgery)
First line ECOG PS 0-1 patients:
CAPOX
>Second line Only in highly selected cases, ECOG PS 0-1
Hepatocellular carcinoma
First line Only in ECOG PS 0-1 and Child A:
sorafenib or lenvatinib
Second line Only in highly selected cases:
cabozantinib or regorafenib
Colorectal cancer
Preoperative treatment (rectal cancer) For cT3b and/or cNþ tumors in the lower rectum and any cT4 tumors:
Long-course capecitabine-based chemoradiation
For all other locally advanced tumors:
Short-course radiotherapy
Adjuvant Three-weekly capecitabine-based regimen preferred
Stage III MSS tumors:
pT3 and pN1: CAPOX for 3 months
pT4N1 or anyTN2: CAPOX for 6 months
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Table 1 Continued
First line Left-sided, RAS and BRAF wild-type, MSS and HER2-negative and age < 75 years:
FOLFOX þ bi-weekly anti-EGFRs
Right-sided and/or RAS mutated and age <75 years:
CAPOX þ bevacizumab
BRAF mutated, right-sided/KRAS mutated with high disease burden. AND age < 70 years:
Modified FOLFOXIRI þ bevacizumab
Unfit or elderly patients:
Capecitabine  bevacizumab
Strongly consider treatment holidays following 4 to 6 months induction.
Capecitabine-based maintenance in case of RECIST response and aggressive disease
Second line FOLFIRI þ bevacizumab
MSI-high:
Six-weekly pembrolizumab
BRAF mutated:
Bi-weekly cetuximab plus oral encorafenib
Third line Bi-weekly anti-EGFR agents if not used in the first-line and only for left-sided, RAS and BRAF wild-type,
HER2-negative tumors.
Consider best supportive care or regorafenib with alternative schedules
Anal cancer
Curative therapy Capecitabine-based chemoradiation or radiotherapy alone for unfit patients
Palliative therapy Carboplatin plus paclitaxel
Advanced neuroendocrine neoplasms
First line Well differentiated GEP-NETs:
SSAs
Poorly differentiated NECs:
Carboplatin plus oral etoposide
Second line Well/moderately differentiated pNETs:
Sunitinib
Well-differentiated small intestinal NETs:
High-dose SSAs or PRRT
Poorly differentiated NECs:
Consider best supportive care or capecitabine þ temozolomide
Abbreviations: CAPOX ¼ capecitabine and oxaliplatin; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; EGFR ¼ epidermal growth factor receptor; FLOT ¼ docetaxel, oxaliplatin,
and fluorouracil/leucovorin; FOLFIRI ¼ folinic acid, 5-fluorouracil, and irinotecan; FOLFIRINOX ¼ folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin; FOLFOX ¼ folinic acid, 5-fluorouracil, and
oxaliplatin; FOLFOXIRI ¼ folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan; GEP-NET ¼ gastroenteropancreatic neuroendocrine tumor; HER2 ¼ human epidermal growth factor receptor 2; MSI ¼
microsatellite instable; MSS ¼ microsatellite stable; NEC ¼ neuroendocrine carcinoma; NET ¼ neuroendocrine tumor; PNET ¼ pancreatic neuroendocrine tumor; PRRT ¼ peptide receptor
radionuclide therapy; RECIST ¼ Response Evaluation Criteria in Solid Tumors; SSAs ¼ somatostatin analogues.
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to first-line treatment, and a first-line treatment-free interval of at
least 3 months.21 Noteworthy, the combination of weekly paclitaxel
and ramucirumab achieved an unprecedented median overall sur-
vival (OS)22 and is frequently used in several countries as the
standard second-line treatment in absence of contraindications to
anti-angiogenics. We selected the modified RAINBOW (mRAIN-
BOW) bi-weekly simplified regimen (paclitaxel 110 mg/m2 plus
ramucirumab 8 mg/kg every 2 weeks) as our standard according to
the MD Anderson study.23 Whenever ramucirumab was contra-
indicated or not available, second-line chemotherapy consisted of 3-
weekly courses of docetaxel or irinotecan (provided pharmacoge-
nomic testing results were available).
Pancreatic Cancer
For patients with resectable pancreatic adenocarcinoma (PAC),
we recommended upfront resection. For borderline resectable dis-
ease, neoadjuvant chemotherapy was indicated only after multidis-
ciplinary discussion and careful evaluation of age, ECOG PS,
comorbidities, and risk factors. Regarding postoperative treatments,
given the survival advantage of adjuvant mFOLFIRINOX (folinic
acid, 5-fluorouracil, irinotecan, and oxaliplatin),24 this tripletnical Colorectal Cancer Month 2020regimen was recommended only for patients with ECOG PS 0 and
age < 70 years—a more selected patient population compared with
the pivotal study. Furthermore, we chose to delay the treatment
start as much as possible and up to 12 weeks after resection.
As far as unresectable ormetastatic PAC is concerned, the 2 standard
first-line regimens are standard-dose FOLFIRINOX25 and nab-
paclitaxel plus gemcitabine.26 Even in the absence of a randomized
comparison between the 2 options, the toxicity profile of the triplet
regimen is clearlyworse27 andmay represent a challenge even for fit and
younger patients. Therefore, we chose nab-paclitaxel plus gemcitabine
as the preferred upfront regimen, with a modified bi-weekly schedule
instead of the classical 3 weeks on/1 week off schedule.28,29 When the
triplet was deemed necessary (ie, for selected patients with locally
advanced or borderline resectable disease), we used the modified
FOLFIRINOX schedule that is commonly used in the adjuvant setting
(irinotecan dose reduced to 150 mg/m2 and omission of the 5-
fluorouracil bolus), due to better tolerability.30 For BRCA-mutated
disease, our standard strategy was initial oxaliplatin-based doublet
chemotherapy for at least 4months followedby treatment breaks in case
of disease control (stop-and-go approach).Maintenance treatment with
oral olaparib was taken into account mostly for patients who had
platinum-induced neuropathy of grade 2 or more. For patients with an
Filippo Pietrantonio et alECOGPS 2 and/or extensive comorbidities, we strongly advised best
supportive care based on a home-delivery model.
Even if no standard second-line treatment is defined yet, there is
evidence on effectiveness and manageable toxicity of such regimens
defined according to what was given as first-line and ECOG
PS.31-33 However, given the very poor prognosis of metastatic PAC
in this extremely palliative setting, we recommended that a second-
line treatment was offered only to patients with a good ECOG PS
and chemosensitive disease.
Biliary Tract Cancers and
Hepatocellular Carcinoma
Although the only curative treatment for biliary tract cancer
(BTC) is surgery, adjuvant oral capecitabine is recommended for
patients with resected BTC based on the results of the BILCAP
trial.34 However, this study was criticized due to its failure to meet
the primary endpoint (OS) in the intention-to-treat population,
with a relapse rate as high as 60%. Considering such issues, we
decided to: (1) delay treatment start as much as possible, giving the
patient time to fully recover from surgery and (2) discuss each case
according to the risk-benefit profile with regard to ECOG PS, age,
comorbidities, and patients’ preferences.
As far as metastatic or unresectable disease is concerned, the
standard initial treatment for patients with a good ECOG PS is the
combination of cisplatin and gemcitabine, which achieved superior
OS compared with gemcitabine alone.35 However, the schedule of
the regimen by Valle et al (on days 1 and 8 every 21 days) requires
multiple accesses to the hospital and abundant hydration and may
cause relevant grade 3 to 4 toxicities, including hematologic ones.
The gemcitabine-based GEMOX (gemcitabine and oxaliplatin)
regimen is considered a reasonable alternative and safer option, also
when considering single-day courses given every 2 weeks.36
Furthermore, CAPOX was non-inferior to GEMOX in terms of 6-
month progression-free survival (PFS) rate in a recent phase III
trial, with a better toxicity profile and less frequent hospital visits.37
Therefore, CAPOX was recommended as the first-line treatment of
choice for ECOG PS 0 to 1 patients with metastatic or unresectable
BTC. For patients with liver-limited unresectable disease, we dis-
cussed, in a multidisciplinary setting, the chance for locoregional
therapy (eg, yttrium-90 radioembolization), when feasible.38 For
patients with an ECOG PS  2 and/or extensive comorbidities, we
strongly advised best supportive care based on a home-deliverymodel.
Regarding second-line treatment, the same considerations
expressed for patients with PAC were valid.39 For IDH1-mutated or
FGFR2 translocated intrahepatic cholangiocarcinoma, patients’ ac-
cess to orally administered selective inhibitors was recommended,
whenever feasible.40,41
For patients with advanced and unresectable hepatocellular car-
cinoma (HCC), oral treatments were prescribed via web-based
telemedicine and continued until symptomatic deterioration or
radiologic progression, whichever occurred first. The tyrosine kinase
inhibitors sorafenib or lenvatinib42 were recommended in the first-
line setting only in patients with ECOG PS 0 or 1 and Child-Pugh
score A. Second-line treatment with cabozantinib43 or regorafenib44
was recommended only in highly selected patients with goodprognostic features. Enrollment in clinical trials with immuno-
therapy agents was discouraged.
Colorectal Cancer
For patients undergoing adjuvant treatment for colon cancer, 3-
weekly capecitabine-based regimens were preferred over biweekly
infusional 5-fluoruracil-based schedules in order to limit the accesses to
hospital.When oxaliplatin was indicated (mainly in the case of stage III
MSS tumors), the limitation of treatment duration to 3 months was
highly recommended in stage III low-risk (pT3 and pN1) tumors.45
In the same perspective, for locally advanced rectal cancer, the
indication to neoadjuvant capecitabine-based long-course chemo-
radiation was carefully pondered and mainly applied to tumors
arising in the lower rectum and staged  cT3b and/or node-
positive, or for cT4 cancers located in any part of the rectum.
Short-course radiotherapy was preferred in all other cases of locally
advanced rectal cancer.
In the metastatic setting, the impact of the first-line therapy is the
most relevant, both on patients’ long-term outcome and on the
potential subsequent steps of treatment, including surgical and other
locoregional approaches. The relative additional benefit from second
and further lines of therapy is much less important, and their intent
is definitely palliative in most of cases.
Therefore, when choosing of the “best” upfront treatment, every
effort was made to limit toxicity while offering the most efficacious
therapy to each individual patient. In patients unfit for a combi-
nation of chemotherapy, the opportunity to start a first-line regimen
was properly evaluated and discussed, with capecitabine  bev-
acizumab as the preferred option.
When an anti-epidermal growth factor receptor (EGFR) mono-
clonal antibody was chosen as first-line targeted agent (mainly in fit
patients with a left-sided, RAS and BRAF wild-type, MSS, and
HER2-negative tumors), it was combined with a 5-fluorouracil-
based doublet. In the case of cetuximab, we used the bi-weekly
schedule, now widely adopted in clinical trials and in the daily
practice because of its equivalent efficacy and safety compared with
the weekly schedule.46
With regard to the choice of the upfront chemotherapy, in fit
patients, the triplet FOLFOXIRI (folinic acid, 5-fluorouracil, oxa-
liplatin, and irinotecan) provides survival benefit as compared with
both oxaliplatin- and irinotecan-based doublets at the price of
increased gastrointestinal and hematologic toxicities.47 The choice
of this intensive and highly active regimen was suggested only for
patients with aggressive cancers, such as those with BRAF mutation,
or with right-sided primary tumor/KRAS mutation and high tumor
burden, or whenever conversion to liver surgery was foreseen in
borderline resectable liver metastases. Because in patients aged 70 to
75 years the risk of grade 3 and 4 diarrhea and neutropenia is
increased, we carefully weighted the use of the triplet in this age
subgroup.48 To minimize the risk of neutropenia, the use of
granulocyte-colony stimulating factor (G-CSF) as primary prophy-
laxis, which is not routinely recommended, was considered, as well
as modified schedules of FOLFOXIRI, with reduced doses of 5-
fluorouracil (2400 mg/m2 instead of 3200 mg/m2) and irinotecan
(150 mg/m2 instead of 165 mg/m2).46Clinical Colorectal Cancer Month 2020 - 5
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an upfront option, the use of capecitabine instead of 5-fluorouracil
was preferred to reduce the frequency of in-hospital infusional
procedures.49
The duration of the induction therapy was limited to 4 to 6
months. If locoregional treatments were not pursuable, de-
intensifying the treatment to maintenance with fluoropyrimidine
and the biologic agent used during induction is generally recom-
mended. However, because the actual benefit of maintenance with
fluoropyrimidine and bevacizumab as compared with treatment
holiday is modest,50 whereas bevacizumab alone does not provide any
advantage,51 we suggested treatment breaks as a reasonable clinical
option. With regard to anti-EGFRs, although continuing 5-
fluorouracil with panitumumab improves PFS when compared with
panitumumab alone,52 themagnitude of benefit frommaintenance as
compared with treatment holiday has not been assessed yet. In gen-
eral, in an effort to adequately assess the cost/effectiveness balance of
each treatment choice, the opportunity to administer maintenance
therapies was limited to patients with high tumor burden (when a
rapid disease progression may deeply impair subsequent chances of
therapy) and/or those who experienced objective response rather than
disease stabilization in previous disease assessments.
With regard to second-line chemotherapy, minimizing toxicity
was our primary aim, given the outbreak situation. As a conse-
quence, if the inhibition of angiogenesis beyond progression was the
preferred strategy, bevacizumab was chosen over aflibercept and
ramucirumab owing to the increased incidence of gastrointestinal
and hematologic chemotherapy-related adverse events observed with
aflibercept53 and the higher occurrence of neutropenia with ramu-
cirumab.54 In patients bearing BRAF V600E-mutated tumors, the
combination of cetuximab and encorafenib was considered a valid
option with manageable toxicity profile in the second and third line,
based on results of the phase III BEACON trial.55 Though in the
absence of data in this specific setting, the bi-weekly schedule of
cetuximab appears safe and therefore preferable.
Finally, in the patients who were chemorefractory, we carefully
evaluated the option of best supportive care based on the assessment
of individual patients’ life expectancy56 and comorbidities. Two
guideline-recommended third-line oral therapies are available: the
multikinase inhibitor regorafenib is associated with fatigue, hand
and foot skin reaction, skin rash, hypertension, and aspartate
aminotransferase/alanine aminotransferase elevation as the most
frequent adverse events, whereas neutropenia and anaemia more
frequently occur with the novel fluoropyrimidine trifluridine/tipir-
acil. Therefore, though the safety profile of trifluridine/tipiracil
seems to affect patients’ quality of life much less than regorafenib
and thus its use is more frequently favored, in the frame of the
COVID-19 outbreak, avoiding neutropenia and its consequences
was regarded as of paramount importance, thus leading to widen the
potential indications for the use of regorafenib. The registrative
schedule (160 mg/daily 3 weeks on/1 week off) was not recom-
mended, although other schedules of dose escalation, developed to
reduce the toxicity burden, were implemented.57
Out of the frame of clinical trials, therapies supported by low
levels of evidence (ie, anti-EGFR rechallenge or chemotherapy
reintroduction, anti-HER2 strategies, alkylating agents in MGMT
methylated tumors) were not administered.nical Colorectal Cancer Month 2020Anal Cancer
Concomitant chemoradiation using 5-fluorouracil plusmitomycin
is the standard approach for most patients with localized anal squa-
mous cell carcinoma (ASCC) and is able to achieve long-term disease
cure in up to 82% of patients. Even if randomized trials showed the
superiority of chemoradiation over radiotherapy alone in terms of
disease-free survival, local control, and colostomy-free survival, noOS
differences were observed.58 Thus, we considered radiation treatment
alone in patients with lower risk of local relapse, such as those with
cT1-2N0 disease. For patients with locally advanced disease, we
weighed up the use of oral capecitabine as a radiosensitizer as a
reasonable treatment alternative to infusional 5-fluorouracil.59
Finally, HIV-associated patients with ASCC are at higher risk of
developing toxicities from chemoradiotherapy,60 and, due to their
comorbidities, have augmented risk of severe COVID-19. Hence,
we carefully assessed a de-escalation of anticancer treatment in this
peculiar and frail patient category, whereas patients not able to
receive effective highly active antiretroviral therapy (HAART) or
those with CD4þ cell counts less than 200/mL were treated with
radiotherapy alone.
In the setting of metastatic disease, the combination of cisplatin
plus 5-fluorouracil is regarded as the treatment of choice.61
Nevertheless, the recent phase II InterAACT randomized trial of
cisplatin plus 5-fluorouracil versus reduced-dose carboplatin plus
weekly paclitaxel showed superior survival outcomes and reduced
treatment-related toxicity in favor of the experimental arm.62 Based
on these data, the combination of carboplatin/paclitaxel has entered
the clinical practice and was recommended at our hospital.
Gastroenteropancreatic
Neuroendocrine Neoplasms
We recommended the use of somatostatin analogues (SSAs) as one of
the mainstay treatments of well-differentiated gastoenteropancreatic
neuroendocrine tumors (NETs).63 Both octreotide and lanreotide have
very low toxicity and may be administered at patients’ homes. Notably,
because lanreotide does not require reconstitution, it can be injected by a
trained individual (either the patient or a trusted “partner”) without
concern of variability in drug preparation. High-dose SSAs were used
after progression on standard doses. For small intestinal NETs, we
recommended the standard second-line treatment with peptide receptor
radionuclide therapy (PRRT) only after a careful patients' selection
based on high 68Ga-DOTATATE-PET-TC uptake, high tumor
burden, or the presence of tumor-related symptoms, adequate bone
marrow function, young age, and good ECOG PS. Of note, severe
lymphopenia occurred in less than 10% of patients in the pivotal phase
III study, and PRRT requires a short hospitalization every 8 weeks.64
In patients with advanced progressive G1-2 pancreatic NETs
(pNETs), we chose to administer further therapy in case of
symptomatic progression and to prefer sunitinib over everolimus
due to the lower risk of immune suppression and interstitial
pneumonia.65,66
For patients with advanced poorly differentiated gastro-
enteropancreatic neuroendocrine carcinomas (NEC G3-4), etopo-
side-platinum combinations are the most commonly used upfront
regimens and are able to achieve high tumor response rates (30%-
50%)63,67 and potential symptom relief. Although the quality of the
available evidence is relatively low, the Nordic NEC trial did not
Filippo Pietrantonio et alshow differences in terms of efficacy between cisplatin- versus
carboplatin-based regimens. Therefore, we chose the short infusion
of carboplatin plus 3 days of oral etoposide with granulocyte-
stimulating factor support for up to 4 to 6 cycles. Second-line
chemotherapy after platinum-containing regimens has not been
established nor compared with best supportive care. Even if oxali-
platin- and irinotecan-based doublets showed some activity,
temozolomide-based regimens showed a promising response
rate.68-70 Therefore, we chose CAPTEM (capecitabine plus temo-
zolomide) as our reference second-line regimen to be adopted for fit
patients with chemosensitive disease, thanks to its 4-weekly
schedule and fully oral administration.
Microsatellite Instability-high
Advanced Solid Tumors
“Universal” MSI testing was performed for all patients with
advanced gastrointestinal adenocarcinomas, and, after failure of at
least 1 prior treatment line, those with MSI-high cancers were
treated as early as possible with off-label use of immune checkpoint
inhibitors.71 Our treatment of choice was the 6-weekly schedule of
pembrolizumab at the flat dose of 400 mg, which was recently
approved by the United States Food and Drug Administration
(FDA) for several indications.72
Pharmacogenetic Testing
Pharmacogenetic testing for DYPD and UGT1A1 genotypes was
recommended in all patients to personalize the starting dose of
fluoropyrimidines and irinotecan, respectively, thus reducing the
risk of hematologic and gastrointestinal toxicities.73
Maintenance of Central Venous
Catheters
Routine maintenance of central venous catheters (CVCs), as well
as the potential complication of such devices, are among the most
common reasons for hospital accesses, particularly for patients with
gastrointestinal cancers. Even if the standard schedule recom-
mended by several guidelines is a 4-week locking with saline solu-
tion plus or minus heparin, delayed schedules (every 8 or 12 weeks)
did not increase the risk of complications in 2 studies.74,75 Based on
these data, despite the absence of randomised trials, the delayed
schedule of CVCs maintenance was recommended at our hospital.
Thromboprophylaxis
COVID-19 has been associated with a hypercoagulable state due to
cytokine release syndrome,76 together with prolonged bed rest and
invasive ventilation, which may result in a higher risk of thromboem-
bolic events and disseminated intravascular coagulation. Treatment
with low molecular weight heparin (LWMH), namely enoxaparin
administered at therapeutic dosages (1 mg/kg twice a day), has shown
initial evidence of reducing mortality in hospitalized patients with
COVID-19 and is recommended as a support treatment in these cases.
Also, it is well-recognized that patients with cancer are at major
risk of thromboembolic events.77 Of note, patients with gastroin-
testinal malignancies, especially advanced gastric and pancreatic
cancers, are at the highest risk, so that thromboprophylaxis is almost
universally recommended in these patients when an anticancer
treatment is initiated.Given these considerations, we recommended proper thrombo-
prophylaxis for patients with advanced gastrointestinal cancers. As
these patients are also at higher risk for bleeding complications,78
LMWH should be considered as the preferred agent over direct
oral anticoagulants in this phase.
Conclusions
The current COVID-19 pandemic represents an unprecedented
challenge to our health care systems. As the Gastrointestinal
Oncology Unit of a referral comprehensive cancer center, we were
faced with the need of changing our day-by-day clinical practice to
cope with the pandemic. Our adaption of standard-of-care treat-
ment regimens was guided mainly by 2 needs: (1) to minimize the
number of hospital visits and hospitalizations, and (2) to prevent
anticancer treatment-induced complications of COVID-19.
COVID-19 created a reality where we needed to decide almost
immediately on what is important and what is of less importance,
instead of making very careful decisions based on large trials and
thoughtful discussions as we, like most oncologists, are used to
doing. Therefore, even if we tried to set up a rigorous method,
inevitably, most measures are based on educated assumptions and
expert opinions, influenced or supported by extrapolated
information.
Despite their limits, we hope that our guidelines might be of
interest for gastrointestinal oncologists who are now beginning to
face the outbreak all over the world.
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